Please select the option that best describes you:
For a patient with IIIC1 (micromets), MSI-high, Grade 2 endometrial adenocarcinoma who has undergone full surgical staging, do you recommend adding immunotherapy to adjuvant chemotherapy + radiation?
Answer from: Radiation Oncologist at Academic Institution
No.RUBY only allowed stage IIIC2, any histology, or stage IIIC1 high-risk histology (carcinosarcoma/serous/clear cell) fully resected patients to be enrolled.NRG-GY018 did not allow any fully resected stage III patient to be included. All stage III patients needed to have unresected gross disease.
Comments
Radiation Oncologist at Johns Hopkins University/Sidney Kimmel Cancer Center
I agree. Important to note that only 18.6% of pati...
I agree. Important to note that only 18.6% of pati...
at BayCare Medical Group
Where does it state only fully resected patients w...
Where does it state only fully resected patients w...
Radiation Oncologist at Legacy Health System
To clarify from RUBY: "Patients who were ...
To clarify from RUBY: "Patients who were ...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
Dr. @Corey, I presume your patient had a post-op P...
Dr. @Corey, I presume your patient had a post-op P...
Radiation Oncologist at Legacy Health System
It is important to remember that in RUBY patients ...
It is important to remember that in RUBY patients ...
at BayCare Medical Group
Why is RT presumed more curative than chemotherapy...
Why is RT presumed more curative than chemotherapy...
at H. Lee Moffitt Cancer Center and Research Institute
Very good question and one we struggle with (but m...
Very good question and one we struggle with (but m...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
In the adjuvant setting (no gross disease), there ...
In the adjuvant setting (no gross disease), there ...
at BayCare Medical Group
To answer your question, "Is there a sugge...
To answer your question, "Is there a sugge...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
GOG 258 is a trial of comparing two adjuvant thera...
GOG 258 is a trial of comparing two adjuvant thera...
Answer from: Radiation Oncologist at Academic Institution
KEYNOTE-B21 has been published which now supports the use of immunotherapy in fully resected stage III patients that are dMMR, relevant to this clinical scenario, based on a PFS benefit.Van Gorp et al., PMID 39284383Slomovitz et al., PMID 39411812
Comments
Radiation Oncologist at Legacy Health System
It is interesting to note that the authors did not...
It is interesting to note that the authors did not...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
Good catch on DFS vs PFS - I use them interchangea...
Good catch on DFS vs PFS - I use them interchangea...
Very nice summary of data to help guide all of us....
Great up to date summary